Effectiveness of pharmacist intervention in patients with chronic kidney disease

International Journal of Clinical Pharmacy

Volumn 36, Issue 5, 2014, Pages 896-903

  Cabello Muriel, Aurelio ^a   Gascón–Cánovas, Juan José ^b   Urbieta Sanz, Elena ^a   Iniesta Navalón, Carles ^a  

^a HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

Author keywords

Chronic kidney disease; Dose adjustment; Hospitalized patients; Internal medicine department; Nephrotoxic drugs; Pharmacist intervention; Renal function; Spain

Indexed keywords

ALLOPURINOL; AMINOGLYCOSIDE DERIVATIVE; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COLCHICINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GENTAMICIN; GLYCOPEPTIDE; HYDROCHLOROTHIAZIDE; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANITIDINE; TEICOPLANIN;

AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE CLEARANCE; FEMALE; GLOMERULUS FILTRATION RATE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OUTCOME ASSESSMENT; PATIENT MONITORING; PHARMACIST; CONTROLLED CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; PATHOPHYSIOLOGY; PATIENT ATTITUDE; PHYSIOLOGIC MONITORING; PHYSIOLOGY; PROFESSIONAL STANDARD; PROSPECTIVE STUDY; PSYCHOLOGY; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME; VERY ELDERLY;

AGED, 80 AND OVER; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MONITORING, PHYSIOLOGIC; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PATIENT ACCEPTANCE OF HEALTH CARE; PHARMACISTS; PROFESSIONAL ROLE; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84911455787     PISSN: 22107703     EISSN: 22107711     Source Type: Journal    
DOI: 10.1007/s11096-014-0001-3     Document Type: Article

References (29)

1. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adults US population: Third Natinonal Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1–12.
2. Levey AS, Coresh J, Balk E, et al. National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–47.
3. Otero A, de Francisco ALM, Gayoso P, García F, et al. Prevalence of chronic renal disease in Spain: results of the EPIRCE study. Nefrología. 2010;30:78–86.
4. Chertow GM, Lee J, Kuperman GJ, Burdick E, Horsky J, Seger DL, et al. Guided medication dosing for inpatients with renal insufficiency. JAMA. 2001;286:2839–44.
5. Alvarez L, Climent E, Bosacoma N, Roca S, Perdiguero M, Ordovás JP, et al. Evaluación de un programa de intervención farmacéutica en pacientes con medicamentos de riesgo renal [Evaluation of a pharmaceutical intervention program in patients with renal risk drugs]. Farm Hosp. 2009;33:147–54 Spanish.
6. Remuzzi G, Ruggenenti P, Perico N. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med. 2002;136:604–15.
7. Blix HS, Viktil KK, Moger TA, Reikvam A. Use of renal risk drugs in hospitalized patients with impaired renal function-an understaimated problem? Nephrol Dial Transplant. 2006;21:3164–71.
8. Fabregas X, Agustí C, Gurrera T, Felip A. Evaluación de la intervención farmacéutica en un programa de reajuste de dosis en pacientes con función renal alterada [Evaluation of pharmaceutical intervention in a dose adjustment program in patients with impaired renal function]. Farm Hosp. 2003;27(Supl 1):28. Spanish.
9. Falconnier AD, Haeffeli WE, Schonenberger RA, Surber C, Martin-Facklam M. Drug dosage in patients with renal failure optimized by inmediate concurrent feedback. J Gen Intern Med. 2001;16:369–75.
10. Lavilla FJ, Ferrer A. Fracaso renal agudo: clasificación, etiopatogenia y factores pronósticos [Acute renal failure: classification, pathogenesis and prognostic factors]. Medicine. 2011;10:5348–55 Spanish.
11. Long CL, Raebel MA, Price DW, Magid DJ. Compliance with dosing guidelines in patients with chronic kidney disease. Ann Pharmacother. 2004;38:853–8.
12. Sweileh WM, Janem SA, Sawalha AF, Abu-Taha AS, Zyoud SH, Sabri IA, et al. Medication dosing errors in hospitalized patients with renal impairment: a study in Palestine. Pharmacoepidemiol Drug Saf. 2007;16:908–12.
13. Salomon L, Deray G, Jaundon MC, Chebaiser C, Bossi P, Launay-Vacher V, et al. Medication misuse in hospitalized patients with renal impairment. Int J Qual Health Care. 2003;15:331–5.
14. Salgado TM, Moles R, Benrimoj SI, Fernandez-Llimos F. Pharmacist´s interventions in the management of patients with chronic kidney disease: a systematic review. Nephrol Dial Transplant. 2011;0:1–17.
15. Pai AB, Boyd A, Depczynski J, et al. Reduced drug use and hospitalization rates in patients undergoing hemodialysis who received pharmaceutical care: a 2-year, randomized, controlled study. Pharmacotherapy. 2009;29:1433–40.
16. Leung WY, So WY, Tong PC, et al. Effects of structured care by a pharmacist-diabetes specialist team in patients with type 2 diabetic nephropathy. Am J Med. 2005;118:1414.
17. Bucaloiu ID, Akers G, Bermudez MC, et al. Outpatient erythropoietin administered through a protocol-driven, pharmacist-managed program may produce significant patient and economic benefits. Manag Care Interface. 2007;20:26–30.
18. Yokum D, Glass G, Cheung CF, et al. Evaluation of a phosphate management protocol to achieve optimum serum phosphate levels in hemodialysis patients. J Ren Nutr. 2008;18:521–9.
19. Leal S, Soto M. Chronic kidney disease risk reduction in a Hispanic population through pharmacist-based disease-state management. Adv Chronic Kidney Dis. 2008;15:162–7.
20. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–266.
21. Grupo de trabajo de Farmacia y Nefrología. Guía de dosificación de fármacos en insuficiencia renal. HGU Reina Sofía Murcia [Guide to drug dosage in renal failure. HGU Reina Sofia Murcia].2012.Unidad Técnica de Comunicación. Spanish.
22. Mensa J, Gatell JM, Garcia-Sanchez JE, Letang E, Lopez-Suñe E, Marco F. Guía de terapéutica antimicrobiana [Guide antimicrobial therapy] 2011. Ed Antares. 2011.Spanish.
23. Fichas técnicas de los medicamentos. Agencia Española de Medicamentos y Productos Sanitarios. http://www.aemps.gob.es/cima/fichasTecnicas.do?metodo=detalleForm. [Last cited 6- 2012].
24. David N, Robert C, George M, Henry F, Michael S, The Sanford guide to Antimicrobial Therapy 2011. Forty-first edition. 2011.
25. Machin D, Campbell M, Fayers P, Pinol A. Sample size tables for clinical studies. 2nd ed. Blackwell Science; 1997.
26. Devesa C, Matoses C, Peral L, Sanz G, Murcia AC, Navarro A. Atención farmacéutica en pacientes ingresados con insuficiencia renal [Pharmaceutical care in patients hospitalized with kidney failure]. Farm Hosp. 2012;36:483–91 Spanish.
27. Montañés-Paul B, Sáez-Lleó C, Martínez-Romero G. Ajuste de dosificación de medicamentos en pacientes ancianos institucionalizados con insuficiencia renal [Adjust dosage of drugs in institutionalized elderly patients with renal insufficiency]. Farm Hosp. 2009;33:43–7 Spanish.
28. Nyman H, Dowling T, Hudson J, Peter W, Joy M, Nolin T, et al. Comparative evaluation of the Cockcroft-Gault equation and the modification of diet in renal disease (MDRD) study equation for drug dosing. Pharmacotherapy. 2011;31:1130–44.
29. Stevens L, Nolin T, Richardson M, Feldman H, Lewis J, Rodby R, et al. Comparasion of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney. 2009;54:33–42.